Funding Opportunity PA-17-467 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the submission of investigator-initiated research grant applications to support the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest.

Funding Opportunity PA-17-468 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the submission of investigator-initiated research grant applications to support the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest.

Notice NOT-DE-17-012 from the NIH Guide for Grants and Contracts

Notice NOT-EB-17-010 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-081 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-17-026 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

Funding Opportunity RFA-CA-17-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of several Translational Research Centers (TRCs, to be supported by this U01 FOA) and a Data Management and Coordinating Center (DMCC, to be supported a companion U24 FOA, RFA-CA-17-028). The TRCs will conduct studies to improve the surveillance of liver cancer in members of high-risk populations, increase the fraction of liver cancer detected at an early stage, and better stratify patients at risk of developing liver cancer. Research to be conducted by TRCs must be based on appropriate range of biospecimens from cohorts that are focused on cirrhotic patients. A major collaborative effort of the TRCs will be the establishment of a well annotated repository of biospecimens. Biospecimens (blood, other body fluids, and, when feasible, liver tissue) may be already available and/or may be prospectively collected.

Funding Opportunity RFA-CA-17-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of a Data Management and Coordinating Center (DMCC, to be supported by this U24 FOA) and several Translational Research Centers (TRCs, to be supported by the companion U01 FOA, RFA-CA-17-025). The TRCs will conduct studies to improve the surveillance of liver cancer in high-risk populations, increase the fraction of liver cancer detected at an early stage, and better stratify patients at risk of developing liver cancer.

Funding Opportunity PAR-17-338 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications to support the maintenance and follow-up of existing epidemiology cohorts prospectively following at least 2,000 participants. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) will support the conduct of a minimal content exam/data collection cycle, and ascertainment/adjudication of events of clinical significance. The primary goal of this FOA is to maintain and maximize investments in existing prospective cohorts by supporting the infrastructure needed to facilitate resource sharing with the broader scientific communities, and prepare for future innovative research opportunities. This FOA aims to establish the foundational framework for innovative research hypotheses to be funded through ancillary research.

Funding Opportunity PAR-17-465 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase l trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/assets/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental therapies), or use of computational algorithms. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use.

Funding Opportunity RFA-DK-17-011 from the NIH Guide for Grants and Contracts. The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research must reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.

Funding Opportunity RFA-DK-17-506 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition is to extend the Chronic Renal Insufficiency Cohort (CRIC) Study by continuing to support the Scientific and Data Coordinating Center. The CRIC Study is a multi-center, prospective, observational cohort study of men and women with chronic kidney disease (CKD). The operational components of the study include seven Clinical Centers and a Scientific and Data Coordinating Center (SDCC). The CRIC Study, established in 2001, has recruited approximately 5,500 study participants and followed them with annual in-person clinic visits and interim telephone contacts. The SDCC provides key leadership functions for this study in the areas of study organization, study design and implementation, overall management, and data management and analysis. The CRIC Clinical Centers will continue to follow-up previously enrolled participants under a separate FOA with a focus on developing novel methods for clinical assessment of CKD and associated cardiovascular diseases (CVD) risk factors. It is expected that these novel assessment methods, combined with new analytic approaches, will identify endophenotypes of CKD, develop associations with CKD progression and acute kidney injury, and more fully characterize these diseases and their associated cardiovascular sequalae. It is anticipated that these studies will provide important insights into the courses and consequences of CKD and CVD for both health care providers and their patients with CKD to improve their management, including informing future clinical trials to reduce the burden of these chronic and varied diseases. The SDCC will lead the study group to achieve the scientific goals of the next project period.

Funding Opportunity RFA-DK-17-505 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition is to extend the Chronic Renal Insufficiency Cohort (CRIC) Study by continuing to support Clinical Centers that have previously enrolled and followed study participants. The CRIC Study is a multi-center, prospective, observational cohort study of men and women with chronic kidney disease (CKD). The operational components of the study include seven Clinical Centers and a Scientific and Data Coordinating Center (SDCC). The CRIC Study, established in 2001, has recruited approximately 5,500 study participants and followed them with annual in-person clinic visits and interim telephone contacts. The primary objective of this FOA is to continue the follow-up of enrolled participants with a focus on developing novel methods for clinical assessment of CKD and associated cardiovascular disease (CVD) risk factors. The expectation is that these novel assessment methods, combined with new analytic approaches, will identify endophenotypes of CKD, develop associations with CKD progression and acute kidney injury, and more fully characterize these diseases and their associated cardiovascular sequalae. It is anticipated that these studies will provide important insights into the courses and consequences of both CKD and CVD for health care providers and their patients with CKD to improve their management, including informing future clinical trials to reduce the burden of these chronic and varied diseases.

Notice NOT-AR-17-019 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-006 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-004 from the NIH Guide for Grants and Contracts

Notice NOT-HD-17-017 from the NIH Guide for Grants and Contracts

Notice NOT-HG-17-013 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-535 from the NIH Guide for Grants and Contracts

Notice NOT-FD-17-012 from the NIH Guide for Grants and Contracts